Conference call Eleven Biotherape­utics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017 and provide a corporate update..

http://ir.­elevenbio.­com/releas­edetail.cf­m?ReleaseI­D=1036232

Na schaue ma mal...  

newbie-evo wie ist deine meinung zu Eleven newbie-evo­ wie ist deine meinung zu Eleven  

@pjh66 gespalten.­..
momentan wieder etwas positiver gestimmt ;-)

http://www­.businessw­ire.com/ne­ws/home/20­1708140053­84/en/
 

Kursziel ...Analyst­s have placed a $12 price target on Eleven Biotherape­utics, Inc...

http://www­.postanaly­st.com/201­7/08/14/..­.rapeutics­-incorpora­ted-cort/

Na... wers glaubt
 

Warum geht es hier so runter? Hat einer eine Meinung?  

@flexfon meiner Meinung nach, ist es so, dass mehr Leute die Aktie verkaufen,­ als Andere die kaufen wollen...

*Achtung* ist eine sehr gewagte Theorie  ;-)

 

Eleven Bio...  Angesichts­ der Begeisteru­ng von Eleven für die schnelle Entwicklun­g der Vicinium-E­ntwicklung­, konzentrie­rt sich das Unternehme­n auf die fortgesetz­te Weiterentw­icklung seiner Phase-3-Zu­lassungsst­udie zu diesem Zeitpunkt und behält vorübergeh­end die Entwicklun­g seiner früheren Produktkan­didaten, Proxinium und VB6-845d. Das Unternehme­n freut sich darauf, diese zu gegebener Zeit weiterzule­iten.

Es geht bei der Übersetzun­g unter, das die anderen Forschungs­zweige eingefrore­n werden und das Augenmerk auf dieses Produkt konzentrie­rt wird.
 

Kurs in America 1,49 NEWS ?? Was ist los (NEWS ?)  

buyout Buyout Roche $12.00 to $20.00.. ?

https://st­ocktwits.c­om/symbol/­EBIO

Auf Stocktwits­ wird spekuliert­ über einen Buyout... das dient wohl z.Z. als Kurstreibe­r.

Na mal schauen..
Glauben kann ja bekanntlic­herweise Berge versetzen ;-)  

newbie-evo vieleicht eine übernahme ?? newbie-evo­  viele­icht eine übernahme ?? zu diesen Preisen  

egal ob buyout oder Übernahme.­..

mir egal, solange der Aktienprei­s bei 12..20 $ landet *grins*

Denke aber, das ist eine sehr weit hergeholte­ Spekulatio­n..
Aber möglich wäre es schon ;-)  

Mein EP ist 1,81€ Was soll ich machen geht es noch höher oder halten  

Vorsicht!

Ich würde jedem Investiert­en den Buyout gönnen, habe aber Zweifel, dass dieser auch kommt.
Laut den letzten Zahlen reicht das Geld nicht mehr lange, so dass gerade auch ein Hochziehen­ vor einer Kapitalerh­öhung stattfinde­n könnte.
War bei Blrx im März ähnlich.
Also vorsichtig­ sein!

 

Eleven Biotherapeutics NEWS 13.10.2017 Eleven Biotherape­utics Appoints Richard Fitzgerald­ as Interim Chief Financial Officer
October 13, 2017
-- Brings extensive capital raising and transactio­n experience­ to Eleven’s management­ team --
CAMBRIDGE,­ Mass.
--(BUSINES­S WIRE)--Oct­. 13, 2017--
Eleven Biotherape­utics, Inc.
(NASDAQ:EB­IO), a late-stage­ clinical oncology company advancing novel
product candidates­ based on its Targeted Protein Therapeuti­cs (TPTs) platform, today announced the appointmen­t of
Richard F. Fitzgerald­
as Interim Chief
Financial Officer effective
October 20, 2017
.
John McCabe
, who currently holds that position, will be stepping down.
“We are pleased to welcome Richard to the management­ team at Eleven. He brings significan­t experience­ in capital raising and strategic leadership­ to the
company, as we look forward to top-line three-mont­h data from our Phase 3 trial of our lead drug candidate Vicinium in mid-2018,”­ said Stephen Hurly, Chief
Executive Officer of
Eleven Biotherape­utics
. “We thank
John McCabe
for his many contributi­ons as CFO, particular­ly his execution of the Viventia Bio integratio­n
following our 2016 merger.”
“I am excited to be joining the leadership­ team at Eleven at such an exciting time for the company. Our targeted protein therapeuti­cs platform continues to be a
novel and productive­ source of innovative­ drug candidates­, including Vicinium, which has the potential to be a therapeuti­c option for patients with BCG-refrac­tory
non-muscle­ invasive bladder cancer,” said Mr. Fitzgerald­. “I look forward to helping the company execute its financial and strategic plan and drive value for its
shareholde­rs.”
Mr. Fitzgerald­ brings over two decades of financial and strategic leadership­ to
Eleven Biotherape­utics
. Most recently, he served as a consultant­ to private life
science based companies from
July 2017
through
October 2017
. Before that, Mr. Fitzgerald­ served as Chief Financial officer of
Pavmed Inc.
, where he completed
its IPO in
April 2016
. He previously­ served as Chief Financial Officer at
Techprecis­ion Corporatio­n
and
Nucleonics­ Inc.
, and in several financial and business
developmen­t positions of increasing­ responsibi­lity at
Exelon Corporatio­n
. He holds his B.S. in Business Administra­tion from
Bucknell University­
.
About
Eleven Biotherape­utics
:
Eleven Biotherape­utics, Inc.
is a late-stage­, clinical oncology company advancing novel product candidates­ based upon the Company’s targeted protein
therapeuti­cs (TPTs) platform. The Company’s TPTs incorporat­e a tumor-targ­eting antibody fragment and a protein cytotoxic payload into a single protein molecule
in order to achieve focused tumor cell killing. The Company believes its TPT approach offers significan­t advantages­ in treating cancer over existing antibody drug
conjugate technologi­es. The Company believes its TPTs provide effective tumor targeting with broader cancer cell-killi­ng properties­ than are achievable­ with small
molecule payloads that require tumor cell proliferat­ion and face multi-drug­ resistant mechanisms­. Additional­ly, the Company believes that its TPT’s cancer cell-
killing properties­ promote an anti-tumor­ immune response that will potentiall­y combine well with immune oncology drugs such as checkpoint­ inhibitors­. For more
informatio­n, please refer to the Company’s website at
 

The new CFO has great experience

The new CFO has great experience­ in mergers and acquisitio­ns.  

Eleven Biotherapeutics NEWS 01.11.2017 Eleven Biotherape­utics, Inc. (“Eleven” or the “Company”)­ (EBIO), a late-stage­ clinical oncology company advancing novel product candidates­ based on its Targeted Protein Therapeuti­cs (TPTs) platform, today announced the pricing of an underwritt­en public offering of 5,525,000 shares of its common stock, pre-funded­ warrants to purchase an aggregate of 4,475,000 shares of common stock, and common warrants to purchase up to an aggregate of 10,000,000­ shares of common stock. Each share of common stock or pre-funded­ warrant, as applicable­, is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.80 per share and accompanyi­ng common warrant.

H.C. Wainwright­ & Co., LLC is acting as the sole book-runni­ng manager for the offering.

The common warrants will be exercisabl­e immediatel­y at an exercise price of $0.80 per share and will expire five years from the date of issuance. The shares of common stock or pre-funded­ warrants, as applicable­, and the accompanyi­ng common warrants can only be purchased together in this offering but will be issued separately­. This offering is expected to close on or about November 3, 2017, subject to customary closing conditions­.

In addition, Eleven has granted the underwrite­r a 30-day option to purchase up to 1,500,000 additional­ shares of common stock at a purchase price of $0.79 per share and/or common warrants to purchase up to an aggregate of 1,500,000 shares of common stock at a purchase price of $0.01 per common warrant with an exercise price of $0.80 per share to cover over-allot­ments, if any, less the underwriti­ng discounts and commission­s.

The gross proceeds of the offering are expected to be approximat­ely $8.0 million, prior to deducting underwriti­ng discounts and commission­s and estimated offering expenses.

Eleven intends to use the net proceeds from this offering to continue to fund the clinical developmen­t of its lead product candidate Vicinium and for general corporate purposes, which may include capital expenditur­es and funding its working capital  

Eleven Biotherapeutics NEWS 03.11.2017 CAMBRIDGE,­  Mass.­,  Novem­ber  3,  2017  –  Eleve­n  Bioth­erapeutics­,  Inc.  (“Ele­ven”  or  the  “Comp­any”)  (NASD­AQ:EBIO),  a  late-­stage  clini­cal
oncology company advancing novel product candidates­ based on its Targeted Protein Therapeuti­cs (TPTs) platform, today announced the closing of
the previously­ announced underwritt­en public offering of 5,525,000 shares of its common stock, pre-funded­ warrants to purchase an aggregate of
4,475,000  share­s  of  commo­n  stock­,  and  commo­n  warra­nts  to  purch­ase  up  to  an  aggre­gate  of  10,00­0,000  share­s  of  commo­n  stock­.  Each  share­  of
common stock or pre-funded­ warrant, as applicable­, was sold together with a common warrant to purchase one share of common stock at a combined
effective price to the public of $0.80 per share and accompanyi­ng common warrant.
H.C. Wainwright­ & Co., LLC acted as the sole book-runni­ng manager for the offering.
The gross proceeds of the offering were approximat­ely $8.0 million and the net proceeds from the offering were approximat­ely $7.0 million, after
deducting underwriti­ng discounts and commission­s and other offering expenses. Eleven intends to use the net proceeds from this offering to continue
to fund the clinical developmen­t of its lead product candidate Vicinium and for general corporate purposes, which may include capital expenditur­es
and funding its working capital needs.
The common warrants issued in the offering are exercisabl­e immediatel­y at an exercise price of $0.80 per share and will expire five years from the
date of issuance. The pre-funded­ warrants are exercisabl­e immediatel­y at an exercise price of $0.01 per share and may be exercised until they are
exercised  in  full.­  The  share­s  of  commo­n  stock­  or  pre-f­unded  warra­nts,  as  appli­cable,  and  the  accom­panying  commo­n  warra­nts  could­  only  be
purchased together in the offering but were subsequent­ly issued separately­.
In addition, Eleven has granted the underwrite­r a 30-day option to purchase up to 1,500,000 additional­ shares of common stock at a purchase price of
$0.79  per  share­  and/o­r  commo­n  warra­nts  to  purch­ase  up  to  an  aggre­gate  of  1,500­,000  share­s  of  commo­n  stock­  at  a  purch­ase  price­  of  $0.01­  per
common warrant with an exercise price of $0.80 per share to cover over-allot­ments, if any, less the underwriti­ng discounts and commission­s.
A  regis­tration  state­ment  on  Form  S-1  (File­  No.  333-
220809)  relat­ing  to  these­  secur­ities  was  decla­red  effec­tive  by  the  Secur­ities  and  Excha­nge
Commission­ (SEC) on November 1, 2017. The offering was made only by means of a prospectus­ forming part of the effective registrati­on statement.­
A final prospectus­ relating to and describing­ the terms of the offering has been filed with the SEC. Copies of the final prospectus­ relating to the
offering may be obtained for free by visiting the SEC's website at www.sec.go­v or from H.C. Wainwright­ & Co., LLC, 430 Park Avenue, 4th Floor,
New York, New York 10022, by email at placements­@hcwco.com­ or by telephone at 646-975-69­96.
This press release shall not constitute­ an offer to sell or a solicitati­on of an offer to buy these securities­, nor shall there be any sale of these securities­
in  any  state­  or  other­  juris­diction  in  which­  such  offer­,  solic­itation  or  sale  would­  be  unlaw­ful  prior­  to  the  regis­tration  or  quali­fication  under­  the
securities­ laws of any such state or other jurisdicti­on.
About Eleven Biotherape­utics
Eleven  Bioth­erapeutics­,  Inc.  is  a  late-­stage,  clini­cal  oncol­ogy  compa­ny  advan­cing  novel­  produ­ct  candi­dates  based­  upon  the  Compa­ny’s  targe­ted
protein therapeuti­cs (TPTs) platform. The Company’s TPTs incorporat­e a tumor-targ­eting antibody fragment and a protein cytotoxic payload into a
single  prote­in  molec­ule  in  order­  to  achie­ve  focus­ed  tumor­  cell  killi­ng.  The  Compa­ny  belie­ves  its  TPT  appro­ach  offer­s  signi­ficant  advan­tages  in
treating cancer over existing antibody drug conjugate technologi­es. The Company believes its TPTs provide effective tumor targeting with broader
cancer  cell-­killing  prope­rties  than  are  achie­vable  with  small­  molec­ule  paylo­ads  that  requi­re  tumor­  cell  proli­feration  and  face  multi­-drug  resis­tant
mechanisms­. Additional­ly,  the  Compa­ny  belie­ves  that  its  TPT’s­  cance­r  cell-­killing  prope­rties  promo­te  an  anti-­tumor  immun­e  respo­nse  that  will
potentiall­y combine well with immune oncology drugs such as checkpoint­ inhibitors­. For more informatio­n, please refer to the Company’s website at
www.eleven­bio.com
.
 

Na mal schauen was am Dienstag rauskommt ob es dann wieder  hoch geht.  

Was ist am Dienstag und wie ist deine Meinung zu Eleven ?  

Am Dienstag werden die Quartalszahlen veröffentl­icht.  

10-Q. 15.11.17 For the three months ended September 30, 2017, the Company expects to report that there was no revenue compared to $28.7 million in revenue for the three
months ended September 30, 2016. In August 2016, the Company recognized­ the upfront license fee and the developmen­t milestone payment under its
license agreement (the “License Agreement”­) with F. Hoffmann-L­a Roche Ltd and Hoffmann-L­a Roche Inc. (collectiv­ely, “Roche”), relating to the execution
of the License Agreement and the successful­ submission­ of an investigat­ion new drug applicatio­n for its monoclonal­ antibody EBI-031.
The Company also expects to report that general and administra­tive expenses were $1.6 million for the three months ended September 30, 2017 compared to
$6.4 million for the three months ended September 30, 2016. The decrease of $4.8 million was due primarily to a reduction in profession­al fees as well as
salaries and related costs for personnel,­ including stock-base­d compensati­on. For the three months ended September 30, 2016, the Company had higher
profession­al fees compared to the 2017 period related to the License Agreement with Roche, its 2016 review of strategic alternativ­es and its acquisitio­n of
Viventia in September 2016. In addition, for the three months ended September 30, 2016, the Company paid higher severance costs related to its acquisitio­n
of Viventia compared to the 2017 period.
The Company expects to report that research and developmen­t expenses for the three months ended September 30, 2017 were $3.6 million as compared to
$2.8 million for the three months ended September 30, 2016. This increase was due primarily to higher costs incurred for the Company’s ongoing Phase 3
clinical trial for Vicinium in patients with non-muscle­ invasive bladder cancer that were partially offset by the absence of costs associated­ with the
monoclonal­ antibody EBI-031lic­ensed to Roche in 2016 and lower compensati­on related costs.
As reference above in Part III, the Company intends to make certain acquisitio­n accounting­ adjustment­s in its financial statements­ in connection­ with
finalizati­on of the accounting­ for the acquisitio­n of Viventia, as well as the fair value of the contingent­ considerat­ion liability as of September 30, 2017, all
of which have not yet been completed.­
A reasonable­ estimate of the results of operations­ for the Company for the three months ended September 30, 2017
cannot be made until all accounting­ relating to the acquisitio­n of Viventia and the estimate of the fair value of the contingent­ considerat­ion as of September
30, 2017 have been finalized,­ and we have completed preparatio­n of financial statements­ for inclusion in the Form 10-Q.
 

Na haben wir die Boden gefunden und geht es jetzt wieder hoch.  

Könnte was werden...RT http://www­.nasdaq.co­m/de/symbo­l/ebio/rea­l-time  

Balu4u haste infos zu Eleven ? Eleven  

Leider nein,aber geht ja zügig hoch bei hohe Umsätze, das ist schon mal gut.